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An atypical phenotype of hypokalemic periodic 
paralysis caused by a mutation in the sodium channel 
gene SCN4A
Familial hypokalemic periodic paralysis is an autosomal-dominant 
channelopathy characterized by episodic muscle weakness with 
hypokalemia. The respiratory and cardiac muscles typically 
remain unaffected, but we report an atypical case of a family with 
hypokalemic periodic paralysis in which the affected members 
presented with frequent respiratory insufficiency during severe attacks. 
Molecular analysis revealed a heterozygous c.664 C>T transition in 
the sodium channel gene SCN4A, leading to an Arg222Trp mutation 
in the channel protein. The patients described here presented unusual 
clinical characteristics that included a severe respiratory phenotype, an 
incomplete penetrance in female carriers, and a different response to 
medications.
Key words: Hypokalemic periodic paralysis, Respiratory insufficiency, 
Sodium channel
Yang Hee Park, M.D., and June Bum Kim, 
M.D.
Department of Pediatrics, Konyang University College 
of Medicine, Daejeon, Korea 
Received: 29 June 2010, Revised: 17 August, 2010
Accepted: 15 September 2010
Corresponding author: June-Bum Kim, M.D. 
Department of Pediatrics, Konyang University College of 
Medicine, 685 Gasuwon-dong, Su-gu, Daejeon 302-718, 
Korea 
Tel: +82.42-600-9230, Fax: +82.42-600-8835
E-mail: hoppdoctor@hanmail.net 
Copyright © 2010 by The Korean Pediatric Society
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-
nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Introduction
Familial hypokalemic periodic paralysis (OMIM no. 170400) 
is an autosomal-dominant disorder characterized by reversible 
attacks of flaccid paralysis of the skeletal muscles with concomitant 
hypokalemia. The onset of the initial episode occurs within the 
second decade of life, and usually presents during adolescence. 
Paroxysmal muscle weakness mainly develops at night or early in 
the morning, and these episodes usually do not affect the respiratory 
and cardiac muscles. Paralytic attacks are frequently triggered by 
emotional stress, meals rich in carbohydrates and salt, strenuous 
exercise, or cold exposure
1, 2).
Mutations in the CACNA1S gene (OMIM no. 114208), which 
encodes the alpha 1-subunit of the skeletal muscle L-type voltage-
dependent calcium channel, are responsible for the majority (70%) 
of cases of hypokalemic periodic paralysis. Missense mutations in 
the SCN4A gene (OMIM no. 603967), which encodes the skeletal 
muscle voltage-gated sodium channel alpha subunit, account for 
approximately 10% of cases
3, 4).
In this report, we describe a case of familial hypokalemic periodic 
paralysis with unusual clinical manifestations associated with a rare 
mutation in the SCN4A gene. This mutation results in a codon 
change from arginine to tryptophan at residue 222 (Arg222Trp), 
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A 16-year-old boy was referred to our clinic for the evaluation 
of a 6-year history of episodic attacks of flaccid paralysis with 
intermittent respiratory insufficiency. Paralytic attacks had a 
variable frequency, ranging from daily to once every several 
months. However, an acute attack may occur after ingestion of 
carbohydrate- or sodium-rich meals, cold exposure, or vigorous 
exercise. The paralytic attacks mainly affected the hands, the 
feet, or both, and were often generalized and lasted for hours and 
sometimes days. During severe attacks, the patient experienced 
breathing difficulties and was put on ventilator support in a hospital 
several times over the past few years. His father and an uncle had 
similar paralytic attacks; however, the frequency and severity of the 
attacks had decreased in their forties, and the paralytic symptoms 
had occurred rarely in recent years. One of the patient’s uncles had 
died during a severe attack in his twenties (Fig. 1).
At admission, there were no abnormal findings on physical 
examination, electrocardiography, and radiological and laboratory 
evaluations. Holter monitoring for 24 hours did not show structural 
abnormalities. During a severe attack of weakness, however, the 
patient developed numbness in his hands and feet, followed by 
a flaccid paralysis involving the entire body, with a rating of 0 
using the Medical Research Council scale
5). Sensory examination 
revealed no deficits. Deep tendon reflexes were absent in all limbs, 
and Babinski and Hoffmann signs were not present. Cognitive and 
autonomic functions were preserved. Dyspnea with a respiration 
rate of 40 breaths/minute developed after about 1 hour. The heart 
and lungs showed no abnormalities. Blood gas analysis revealed the 
following results: pH, 7.3 (normal, 7.35-7.45); PaCO2, 52 mmHg 
(normal, 35-45 mmHg); HCO3, 25 mEq/L (normal, 22-26 mEq/
L), and a low serum potassium level, 1.5 mEq/L (normal, 3.5-5.0 
mEq/L). Electrocardiography revealed hypokalemic findings, 
such as ST segment depression and prominent U waves. The 
patient developed cyanosis in spite of high flow oxygen delivery 
by a mask, and oxygen saturation was 80%, and was then put 
on ventilator support. Eight hours after intravenous potassium 
chloride infusion, blood potassium level rose to 3.5 mEq/L, and he 
recovered completely from the paralytic symptoms and respiratory 
insufficiency. 
Prophylactic treatment with acetazolamide at a starting dose 
of 250 mg twice daily and a potassium supplement (from 1,200 
mg to 1,800 mg twice daily) were administered to the patient 
and the other affected family members for the symptoms of 
episodic paralysis. This treatment was however ineffective, and 
they were prescribed a combination of oral spironolactone (25 
mg twice daily), amiloride (5-10 mg twice daily), and potassium 
salts (1,200-1,800 mg twice daily). The frequency and intensity of 
their paralytic attacks were markedly reduced after administration 
of this drug combination. Serum electrolyte values, which were 
regularly assessed on an outpatient basis to avoid the possible risk of 
developing hyperkalemia, were within normal ranges throughout 
the combination treatment.
Mutation screening was performed by sequence analysis of 
the entire coding region of the CACNA1S and SCN4A genes. 
Genomic DNA was extracted from the peripheral blood of the 
patient and members of his family using a DNA extraction kit 
(SolGent, Daejun, Korea). All participants provided written 
informed consent, and the study was conducted in compliance with 
the Institutional Review Board of Konyang University Hospital. 
Full exons of the CACNA1S and SCN4A genes were amplified 
to scan for mutations. Primers were designed from the introns 
surrounding the exons using Primer3 software (http://www.
genome.wi.mit.edu/cgi-bin/primer) or VectorNTI10 (Invitrogen, 
Carlsbad, CA, USA). Polymerase chain reaction (PCR) was 
performed using a thermal cycler (GeneAmp PCR System 9700; 
Applied Biosystems, Foster City, CA, USA) in a total volume of 25 
μ L containing 100 ng of genomic DNA, 10 pmol of each primer, 
and 2X H-Taq Multiplex premix, which consisted of PCR buffer, 
deoxyribonucleoside triphosphates, MgCl2, and H-Taq DNA 
polymerase (SolGent). The PCR conditions were as follows: initial 
denaturation at 95℃ for 15 minutes, followed by 35 cycles at 95℃
for 20 seconds, at 60℃ for 20 seconds, and at 72℃ for 30 seconds, 
with final extension at 72℃ for 2 minutes. The PCR products 
were purified using a Millipore FB plate (Millipore, Billerica, 
MA, USA), and were then used as a template for cycle sequencing 
with the BigDye terminator cycle-sequencing ready reaction kit 
(Applied Biosystems, Foster City, CA, USA). Nucleotide sequences 
were determined by using an automatic genetic analyzer (model 
ABI 3730XL; Applied Biosystems). The obtained sequences were 
compared with the sequences from the control samples using 
SeqMan software (DNASTAR, Madison, WI, USA), and sequence 
Fig. 1. Pedigree of the family with hypokalemic periodic paralysis. The 
proband is indicated with an arrow. Asymptomatic mutation carriers are 
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variations were confirmed by analyzing both DNA strands.
Direct sequencing of SCN4A exon 5 revealed a heterozygous 
C>T transition at nucleotide 664 (Fig. 2), leading to the sub-
stitution of a highly conserved, positively charged arginine with a 
tryptophan at codon 222 (Arg222Trp). This mutation was found 
in the clinically affected father, uncle, and cousin, and also in the 
clinically unaffected grandmother and aunt (the cousin’s mother) 
(Fig. 1). Paternity was confirmed using 15 markers provided by the 
PowerPlex 16 system (Promega, Madison, WI, USA). 
Discussion
Mutations in the SCN4A gene have been shown to be re-
sponsible for approximately 10% of cases of hypokalemic periodic 
paralysis
3, 4). Among the mutations of the SCN4A gene that have 
been identified, the Arg222Trp is a very rare mutation that has 
been mentioned in only one previous study to date
4). Reported 
here is the first case of familial hypokalemic periodic paralysis 
with the Arg222Trp mutation from an Asian country. We regard 
this mutation as the cause of clinical presentation of our patients 
based on the following reasons: (1) this mutation is located in 
the S4 segment of domain I, a functionally important part that 
confers voltage-sensing properties to the sodium channel, (2) 
the alteration of the critical S4 regions has been associated with 
loss of normal channel function and (3) arginine mutations in 
S4 segments account for 90% of hypokalemic periodic paralysis 
cases
4). Confirmation of functional significance in a bioassay or 
in additional reports of affected patients with the same mutation 
will help to further establish the pathogenic role of the Arg222Trp 
mutation.
The patients described in this report possess an atypical 
respiratory phenotype responsible for sudden episodes of breathing 
difficulty. Death due to paralysis of the respiratory muscles or 
arrhythmic complications during attacks in hypokalemic periodic 
paralysis has been considered exceptionally rare
2). However, the 
respiratory and cardiac muscles have been reported to be affected 
in patients with hypokalemic periodic paralysis
6, 7), and the 
paralytic attacks described here can be potentially life-threatening. 
Although genotype-to-phenotype correlations have been described 
in hypokalemic periodic paralysis
8), respiratory insufficiency has 
not previously been reported in association with the Arg222Trp 
mutation in the SCN4A gene. The presence of respiratory failure 
in the patient described here may be the result of ethnic differences; 
environmental factors; or perhaps, the Arg222Trp mutation per 
se. This mutation is so rare that a full description of its phenotypic 
correlates is yet to be reported.
Incomplete penetrance of mutations of the SCN4A gene in 
patients with hypokalemic periodic paralysis was reported in a 
Chinese family with the Arg672His mutation
9). In the present 
case, the patient’s grandmother and aunt, who had three and 
one genetically and clinically affected sons, respectively, had the 
Arg222Trp SCN4A mutation, but had never experienced paralytic 
symptoms. This is the first report of incomplete penetrance 
associated with the Arg222Trp mutation. 
Acetazolamide has been considered highly effective in the 
treatment of patients with hypokalemic periodic paralysis
10). 
However, in some patients with either a specific calcium channel 
mutation or a sodium channel mutation, no effect and even 
worsening of the paralytic symptoms have been reported after 
acetazolamide treatment
3, 11). Spironolactone and its derivatives have 
been used as alternatives to acetazolamide in those cases in which 
initial empirical therapy with acetazolamide has been ineffective
12, 
13). We initially prescribed acetazolamide to the patients described 
in this report; however, the episodes of muscle weakness did not 
improve in either frequency or severity following acetazolamide 
treatment. In contrast, all patients showed significant improvements 
in paralytic symptoms after the administration of a combination 
of spironolactone, amiloride, and potassium chloride. It remains 
to be elucidated whether the improvements in paralytic symptoms 
in these patients are associated with genetic or allelic variations in 
response to medications. 
In conclusion, the patients described in this report presented with 
unusual clinical manifestations of familial hypokalemic periodic 
paralysis, including a severe respiratory phenotype, an incomplete 
penetrance in women, and a different response to medication. 
Additional reports of patients with the same mutation would help 
clarify the clinical phenotype associated with this rare mutation.
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